```
=> file reg

COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.15       0.15

FILE 'REGISTRY' ENTERED AT 09:12:03 ON 29 JUN 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:  27 JUN  98  HIGHEST RN 207723-15-7
DICTIONARY FILE UPDATES: 28 JUN  98  HIGHEST RN 207723-15-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 14, 1998

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*** YOU HAVE NEW MAIL ***

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=>
Uploading c:\stnexp4\queries\925326.str

L1      STRUCTURE UPLOADED

=> que L1

L2   QUE L1

=> d L1

L1 HAS NO ANSWERS
L1              STR
```



G1 H,Ph

G2 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s L1 sss sam

SAMPLE SEARCH INITIATED 09:12:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L3 0 SEA SSS SAM L1

=> s L1 sss full

FULL SEARCH INITIATED 09:12:39 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 0 TO ITERATE
100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.03

L4 0 SEA SSS FUL L1

=> file beil

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	113.82	113.97

FILE 'BEILSTEIN' ENTERED AT 09:12:46 ON 29 JUN 1998
COPYRIGHT (c) 1998 Beilstein Chemiedaten und Software GmbH, Beilstein Institut fuer Literatur der organischen Chemie

FILE LAST UPDATED: 1 JUN 1998

FILE COVERS 1779 TO 1997.
*** CAS REGISTRY NUMBERS FOR 4,355,940 SUBSTANCES AVAILABLE ***
*** FILE CONTAINS 7,268,893 SUBSTANCES ***

```
**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE   *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE          *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                        *
* FOR PRICE INFORMATION SEE HELP COST                                *
**********************************************************************
```

```
*** YOU HAVE NEW MAIL ***

=> s L1 sss full

FULL SEARCH INITIATED 09:12:55 FILE 'BEILSTEIN'
FULL SCREEN SEARCH COMPLETED -      0 TO ITERATE
100.0% PROCESSED       0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.08

L5            0 SEA SSS FUL L1

=> file caslink

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.00     113.97

FILE 'REGISTRY' ENTERED AT 09:13:08 ON 29 JUN 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

FILE 'MARPAT' ENTERED AT 09:13:08 ON 29 JUN 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

FILE 'MARPATPREV' ENTERED AT 09:13:08 ON 29 JUN 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

FILE 'CAPLUS' ENTERED AT 09:13:08 ON 29 JUN 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

*** YOU HAVE NEW MAIL ***

CLUSTER 'CASLINK' ENTERED

 Predefined command sequences will be executed in
 REGISTRY, MARPAT, MARPATPREV, and CAPLUS.


=> s L1 sss full


S L1 SSS FUL FILE=REGISTRY
FULL SEARCH INITIATED 09:13:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      0 TO ITERATE
100.0% PROCESSED       0 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.02

L6            0 SEA SSS FUL L1
   1 FILES SEARCHED...

S L6 SSS FUL FILE=MARPAT
FULL SEARCH INITIATED 09:13:22 FILE 'MARPAT'
SCREENING
FULL SCREEN SEARCH COMPLETED -  15414 TO ITERATE
 12.1% PROCESSED    1863 ITERATIONS  (     3 INCOMPLETE)        5 ANSWERS
 22.2% PROCESSED    3426 ITERATIONS  (    18 INCOMPLETE)       20 ANSWERS
 36.3% PROCESSED    5599 ITERATIONS  (    33 INCOMPLETE)       35 ANSWERS
 52.5% PROCESSED    8098 ITERATIONS  (    48 INCOMPLETE)       50 ANSWERS
 64.9% PROCESSED   10006 ITERATIONS  (    67 INCOMPLETE)       69 ANSWERS
```

```
 74.7% PROCESSED   11516 ITERATIONS  (    90 INCOMPLETE)      92 ANSWERS
 84.9% PROCESSED   13088 ITERATIONS  (    98 INCOMPLETE)     100 ANSWERS
 90.7% PROCESSED   13984 ITERATIONS  (   105 INCOMPLETE)     107 ANSWERS
 93.4% PROCESSED   14390 ITERATIONS  (   109 INCOMPLETE)     111 ANSWERS
 97.3% PROCESSED   14994 ITERATIONS  (   112 INCOMPLETE)     114 ANSWERS
 99.5% PROCESSED   15337 ITERATIONS  (   113 INCOMPLETE)     115 ANSWERS
 99.7% PROCESSED   15371 ITERATIONS  (   114 INCOMPLETE)     116 ANSWERS
 99.8% PROCESSED   15382 ITERATIONS  (   115 INCOMPLETE)     117 ANSWERS
100.0% PROCESSED   15414 ITERATIONS  (   117 INCOMPLETE)     119 ANSWERS
SEARCH TIME: 00.04.03

L7          119 SEA SSS FUL L1
   1 FILES SEARCHED...

S L7 SSS FUL FILE=MARPATPREV
FULL SEARCH INITIATED 09:17:27 FILE 'MARPATPREV'
FULL SCREEN SEARCH COMPLETED -     35 TO ITERATE
100.0% PROCESSED      35 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.09

L8            0 SEA SSS FUL L1
   1 FILES SEARCHED...

S L6 FILE=CAPLUS
L9            0 FILE CAPLUS
   1 FILES SEARCHED...

SET DUPORDER FILE
SET COMMAND COMPLETED

DUP REM L8 L7 L9
L8 HAS NO ANSWERS
L9 HAS NO ANSWERS
PROCESSING COMPLETED FOR L8
PROCESSING COMPLETED FOR L7
PROCESSING COMPLETED FOR L9
L10         119 DUP REM L8 L7 L9 (0 DUPLICATES REMOVED)
                ANSWERS '1-119' FROM FILE MARPAT

=> s L10/com


S L10/COM FILE=CAPLUS
QUALIFICATION NOT VALID FOR L***
   1 FILES SEARCHED...
Field code qualifications can only be applied to text
terms.
```

L10 ANSWER 118 OF 119 MARPAT COPYRIGHT 1998 ACS
(ALL HITs ARE ITERATION INCOMPLETES)

ACCESSION NUMBER:	114:82562 MARPAT	
TITLE:	Preparation of acyldipeptide amides as tachykinin antagonists	
INVENTOR(S):	Matsuo, Masaaki; Hagiwara, Daijiro; Miyake, Hiroshi	
PATENT ASSIGNEE(S):	Fujisawa Pharmaceutical Co., Ltd., Japan	
SOURCE:	Eur. Pat. Appl., 13 pp. CODEN: EPXXDW	
	NUMBER	DATE
PATENT INFORMATION:	EP 394989 A2	901031
DESIGNATED STATES:	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE	
APPLICATION INFORMATION:	EP 90-107822	900425
PRIORITY APPLN. INFO.:	GB 89-9795	890428
	GB 89-17542	890801
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	

MSTR 3B ITERATION INCOMPLETE



G3 = CO2H / 3



G4 = alkylene<(1-6)> / alkenylene<(2-6)> / (SC CH2 / CH2CH2 / CH2CH2CH2 / CH=CH)
G5 = CH / N
G6 = O / S / 46



G7 = H / R / (SC OH / X / alkyl<(1-6)> / alkoxy<(1-6)> / dialkylamino<(1-6)> / acyl / alkoxycarbonyl<(1-6)> / Cl / Me / OMe / NMe2)

G8 = H / R / (SC alkyl<(1-6)> (SO (1-) CO2H (SO)) / alkyl<(1-6)> (SR (1-) dialkylamino<(1-6)>) / alkyl<(1-6)> (SR (1-) alkylaminocarbonyl<(1-6)> (SR (1-) dialkylamino<(1-6)>)) / alkoxycarbonyl<(1-6)> / alkyl<(1-6)> (SR (1-) alkoxycarbonyl<(1-6)>) / Me / Pr-i / CH2CO2H / 48 / 52 / 57)





DER: or reactive derivatives or salts

(ALL HITs ARE ITERATION INCOMPLETES)

ACCESSION NUMBER:	116:255478 MARPAT	
TITLE:	Preparation of 3-alkylthio-N-benzylindoles and related compounds as leukotriene inhibitors	
INVENTOR(S):	Gillard, John W.; Morton, Howard E.; Fortin, Rejean; Guindon, Yvan	
PATENT ASSIGNEE(S):	Merck Frosst Canada Inc., Can.	
SOURCE:	U.S., 30 pp. Cont.-in-part of U.S. Ser. No. 942,900, abandoned. CODEN: USXXAM	
	NUMBER	DATE
PATENT INFORMATION:	US 5081138 A	920114
APPLICATION INFORMATION:	US 87-130771	871209
PRIORITY APPLN. INFO.:	US 86-942900	861217
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	

MSTR 1 ITERATION INCOMPLETE



G1 = H / alkyl<(1-7)> / cycloalkyl<(3-7)>
G3 = O / S / S(O) / SO2
G4 = alkyl (SO (1-) G14) / cycloalkyl (SO) / alkenyl<(2-6)> / cycloalkenyl<(3-6)> / Ph (SO)
G5 = (1-) H / alkyl (SO (1-) G19) / cycloalkyl<(3-7)> (SO) / alkenyl<(2-6)> / cycloalkenyl<(3-6)> / OH / 126 / F / Cl / Br / I / CF3 / SH / Ph (SO) / CO2H / 129 / CHO / 133 / alkylcarbonyl (SO) / tetrazolyl / NHCHO / 138 / alkylcarbonylamino (SO) / 139 / 143 / 146 / NO2 / OCHO / alkylcarbonyloxy (SO) / 148 / CN /

N3





G6 = (3-) H / alkyl<(1-3)> / F / Cl / Br / I / OH / CN / CF3 / alkoxy<(1-3)> / alkylthio<(1-3)> / CO2H / alkoxycarbonyl<(1-3)> / alkylcarbonyl<(1-3)> / N3 / R

G7 = alkylene / (SC 125-8 123-34)



G8 = CH2OH / 38 / 68



G9 = OH / alkoxy<(1-7)> / cycloalkyloxy<(3-7)> / OPh (SO) / OCH2Ph (SO) / 40 / 46 / 56 / H / NH2 / alkylamino<(1-7)> / cycloalkylamino<(3-7)> / 80 / Hy<EC (1) Q (1) N (2-5) C (0) OTHERQ, AN (1) N, AR (0), BD (ALL) SE, RC (1), RS (1) M3 (1) X6> / 72 / 75 / Hy<EC (2) Q (1) N (1) O (1-4) C (0) OTHERQ, AN (1) N, AR (0), BD (ALL) SE, RC (1), RS (1) M3 (1) X6>





G10 = CF3 / alkyl<(1-7)> / cycloalkyl<(3-7)> / CH2Ph (SO) / Ph (SO)

G11 = NH / 77



G12 = alkyl<(1-7)> / cycloalkyl<(3-7)>
G13 = OH / alkoxy<(1-7)> / cycloalkyloxy<(3-7)>
G14 = OH / 82 / F / Cl / Br / I / CF3 / SH / Ph (SO) / CO2H / 85 / CHO / 89 / alkylcarbonyl (SO) / tetrazolyl / NHCHO / 94 / alkylcarbonylamino (SO) / 95 / 99 / 107 / NO2 / OCHO / alkylcarbonyloxy (SO) / 109 / CN / N3





G15 = O / S / S(O)
G16 = R / NH2 / 102 / 105 / Hy<EC (1-) Q (1-) N, AN (1-) N, RC (1), RS (1) M5 (1) X7>



G17 = NH2 / 113 / 116 / Hy<EC (1-) Q (1-) N, AN (1-) N, RC (1), RS (1) M5 (1) X7> / 118



G18 = CH2 / CH2CH2CH2
G19 = R / OH
DER: and pharmaceutically acceptable salts
MPL: claim 1
NTE: additional ring formation specified

ACCESSION NUMBER:	120:54771 MARPAT
TITLE:	Preparation of .beta.-carbolines as noncompetitive glutamate antagonists.
INVENTOR(S):	Huth, Andreas; Krueger, Martin; Rahtz, Dieter; Seidelmann, Dieter; Turski, Lechoslaw; Loeschmann, Peter Andreas; Stephens, David Norman; Schneider, Herbert
PATENT ASSIGNEE(S):	Schering A.-G., Germany
SOURCE:	Ger. Offen., 7 pp. CODEN: GWXXBX

	NUMBER	DATE
PATENT INFORMATION:	DE 4212529 A1	931014
APPLICATION INFORMATION:	DE 92-4212529	920410
DOCUMENT TYPE:	Patent	
LANGUAGE:	German	

MSTR 1 ITERATION INCOMPLETE



G1 = (1-) H / F / Cl / Br / I / NH2 / NO2 / 19 / Ph (SO (1-) G7) / heteroaryl / OH / 27 / 54 / (EX pyridyl / pyrimidinyl / pyrazinyl / pyridazinyl / furyl / thienyl / pyrrolyl / thiazolyl / imidazolyl / triazinyl)



G2 = H / alkyl<(1-4)>
G3 = H / alkyl<(1-2)> (SO G4) / alkoxy<(1-6)> / alkylthio<(1-6)> / Ph (SO (1-) G24) / 269

G4 = NH2 / 22 / 25 / Hy<EC (1-2) Q (1-) N (0-) O (0-) S (0) OTHERQ, AN (1-) N, AR (0), BD (ALL) SE, RC (1), RS (1) M5 (1) X6> (SO (1-2) G6) / (EX piperidino / morpholino / piperazino / pyrrolidino / 128 / 134 / thiomorpholino / 138 / 145 / 150 / 155 / 160 / 168)





G5 = Ph / alkyl<(1-4)>
G6 = alkyl<(1-4)> / alkoxycarbonyl<(1-4)>
G7 = F / Cl / Br / I / alkoxy<(1-4)> / NH2
G8 = alkyl<(1-6)> / cycloalkyl<(3-7)> / Ph (SO (1-) G24) / 62 / heteroaryl (SO (1-) G24) / Hy<EC (1-) Q, AR (1-), BD (6-) N, RC (2), RS (0-) E5 (1-) E6 (0) OTHER> (SO (1-) G24) / (EX pyridyl / pyrimidinyl / pyrazinyl / pyridazinyl / furyl / thienyl / pyrrolyl / thiazolyl / imidazolyl / triazinyl / quinolinyl / isoquinolinyl / quinoxalinyl / benzimidazolyl)



G9 = OH / NH2 / 32 / 35 / Hy<EC (1-2) Q (1-) N (0-) O (0) OTHERQ (1-5) C, AN (1-) N, AR (0), BD (ALL) SE, RC (1), RS (1) X6> (SO (1-2) G16) / Hy<EC (1-4) Q (1-3) N (-1) O (-1) S (0) OTHERQ, AN (1) N, BD (1-) D, RC (1), RS (1) M5 (1) X6> / (EX piperidino / morpholino / piperazino / pyrrolidino / 81 / 87 / thiomorpholino / 121 / 93 / 98 / 103 / 108 / 116)





G10 = alkyl<(1-6)> / alkenyl<(2-6)>
G11 = alkyl<(1-6)> / alkenyl<(2-6)> / 38 / 40 / NH2 / Hy<EC (1-2) Q (1-) N (0-) O (0-) S (0) OTHERQ, AN (1-) N, AR (0), BD (ALL) SE, RC (1), RS (1) M5 (1) X6> (SO (1-2) G6) / OH / alkoxy<(1-6)> / 42 / cycloalkyl<(3-7)> / Ph (SO (1-) G13) / alkyl<(1-2)> (SR G14) / alkyl<(1-6)> (SO (1-) G15) / (EX piperidino / morpholino / piperazino / pyrrolidino / 175 / 181 / thiomorpholino / 185 / 192 / 197 / 202 / 207 / 215)

















G12 = H / alkyl<(1-4)> / NH2
G13 = F / Cl / Br / I
G14 = Ph (SO (1-) G13) / F / Cl / Br / I
G15 = alkoxy<(1-4)> / NH2 / 45 / 47 / Hy<EC (1-2) Q (1-) N (0-) O (0-) S (0) OTHERQ, AN (1-) N, AR (0), BD (ALL) SE, RC (1), RS (1) M5 (1) X6> (SO (1-2) G6) / OH / F / Cl / Br / I / Ph / alkoxycarbonyl<(1-4)> / CO2H / (EX piperidino / morpholino / piperazino / pyrrolidino / 222 / 228 / thiomorpholino / 232 / 239 / 244 / 249 / 254 / 262)















G16 = alkyl<(1-4)> / alkoxycarbonyl<(1-4)>
G17 = H / Ph / cycloalkyl<(3-7)> / alkyl<(1-6)> / 50



G18 = (1-3) CH2
G19 = OH / 267



G20 = H / alkyl<(1-6)>
G21 = OH / alkoxy<(1-6)> / OCH2Ph / 57 / 60 / NH2 /
Hy<EC (1-2) Q (1-2) N (0-) O (0-) S (0) OTHERQ, AN (1-) N,
AR (0), BD (ALL) SE, RC (1), RS (1) M5 (1) X6> (SO G23)



G22 = alkyl<(1-6)> / alkenyl<(2-6)>
G23 = Ph / alkyl<(1-4)>
G24 = R / (EX F / Cl / Br / I / NO2 / CN / alkyl<(1-4)> /
alkoxy<(1-4)> / NH2 / alkoxycarbonyl<(1-4)> /
alkylthio<(1-4)> / CF3)
G25 = Ph (SO (1-) G24)
G27 = alkyl<(1-6)> / alkyl<(1-4)> (SR alkoxy<(1-4)>) / Ph
G28 = CH2 / O
MPL: claim 1

ACCESSION NUMBER:	123:32955 MARPAT
TITLE:	Preparation of 1H-indole-3-acetic acid hydrazides as sPLA2 inhibitors.
INVENTOR(S):	Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth; Hermann, Robert Bell; Schevitz, Richard Walter
PATENT ASSIGNEE(S):	Lilly, Eli, and Co., USA
SOURCE:	Eur. Pat. Appl., 66 pp. CODEN: EPXXDW

	NUMBER	DATE
PATENT INFORMATION:	EP 620214 A1	941019
DESIGNATED STATES:	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	
APPLICATION INFORMATION:	EP 94-302646	940414
PRIORITY APPLN. INFO.:	US 93-48608	930416
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	

MSTR 1 ITERATION INCOMPLETE



G1 = O / S
G2 = alkyl<(4-20)> (SO (1-) G3) / alkenyl<(4-20)> / alkynyl<(4-20)> / cycloalkyl<(4-12)> / aryl (SO (1-) G4) / 16 / (EX CH2Ph / 114 / 125 / Bu-i / decyl / octadecyl / 134 / 173 / 177 / 190 / 193)







G3 = F / Cl / Br / I
G4 = F / Cl / Br / I / CN / CHO / OH / SH / alkylthio<(1-10)> / alkoxy<(1-10)> / alkyl<(1-10)> / CO2H / NH2 / NHOH
G5 = alkylene
G6 = aryl (SO (1-) G7)
G7 = F / Cl / Br / I / CN / CHO / OH / NO2 / Ph / SH / alkylthio<(1-10)> / alkoxy<(1-10)> / alkyl<(1-10)> / NH2 / NHOH / Hy<EC (5-8) A, RC (1), RS (1) M5 (1) X8> (SO)
G8 = F / Cl / Br / I / alkyl<(1-3)> / CH=CH2 / alkylthio<(1-2)> / alkoxy<(1-2)> / CHO / CN / (SC SMe) / (EX Me / Et / Pr-n / S(O)Me)
G9 = 20 / 23 / 26 / (EX CHMe / 208)



G10 = H / F / Cl / Br / I
G11 = alkyl<(1-3)>
G12 = H / alkyl<(1-10)> (SO (1-) G3) / alkenyl<(2-10)> / alkynyl<(2-10)> / cycloalkyl<(3-8)> / aryl / aralkyl / alkoxy<(1-10)> (SO (1-) G3) / cycloalkyloxy<(4-8)> / OPh / F / Cl / Br / I / OH / CO2H / SH / CN / alkylthio<(1-10)> / arylthio / R / alkoxycarbonyl<(1-10)> / NHNH2 / NH2 / NO2 / NH2 / alkylamino<(1-10)> (SO OH) / dialkylamino<(1-10)> (SO OH) / Hy<EC (1-) N, AN (1-) N, RC (1), RS (1) M5 (1) X8> / 35 / 37 / 96 / (EX OEt / 106 / OMe / Me / OCH2Ph / Ph / Bu-t / 207 / 212)





G13 = NH2 / alkylamino<(1-10)> (SO OH) / dialkylamino<(1-10)> (SO OH) / Hy<EC (1-) N, AN (1-) N, RC (1), RS (1) M5 (1) X8>
G14 = alkylene (SO OH) / 99



G15 = 39 / 42 / 48 / SO3H / 54 / 64 / 65 / 83 / CO2H / alkoxycarbonyl<(1-10)> / 87





G16 = OH / alkoxy<(1-10)>
G18 = (1-8) CH2
G19 = NH2 / alkylamino<(1-10)> / dialkylamino<(1-10)> / 73



G21 = alkyl<(1-10)>
G22 = OH / alkoxy<(1-10)>
G23 = O / 97 / NH / S



G24 = alkyl<(1-10)>
G25 = Ak<BD (ALL) SE> (SO OH)
G26 = 132 / 141 / 147 / 155 / 163 / pyridyl / 181







G27 = Cl / OMe
G28 = Cl / Me / CF3 / OMe / 174 / OCH2Ph / OH / NO2 / NH2



G29 = Cl / OMe / OCH2Ph / OH
DER: and pharmaceutically acceptable salts and/or metal salts
MPL: claim 1
NTE: additional ring formation specified

ACCESSION NUMBER:	123:32954 MARPAT
TITLE:	Preparation of 1H-indole-3-acetamides as sPLA2 inhibitors.
INVENTOR(S):	Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth; Hermann, Robert Bell; Schevitz, Richard Walter
PATENT ASSIGNEE(S):	Lilly, Eli, and Co., USA
SOURCE:	Eur. Pat. Appl., 123 pp. CODEN: EPXXDW

	NUMBER	DATE
PATENT INFORMATION:	EP 620215 A1	941019
DESIGNATED STATES:	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	
APPLICATION INFORMATION:	EP 94-302666	940414
PRIORITY APPLN. INFO.:	US 93-48629	930416
	US 94-208721	940315

DOCUMENT TYPE:	Patent
LANGUAGE:	English

MSTR 1 ITERATION INCOMPLETE



G1 = O / S
G2 = alkyl<(6-20)> (SO (1-) G3) / alkenyl<(6-20)> / alkynyl<(6-20)> / cycloalkyl<(4-12)> / aryl (SO (1-) G4) / 15 / 17 / (EX Ph / naphthyl / 103 / 113 / 123 / 129 / 133 / 143 / 153 / biphenylyl)









G3 = F / Cl / Br / I
G4 = F / Cl / Br / I / CN / CHO / OH / NO2 / SH / alkylthio<(1-10)> / alkoxy<(1-10)> / alkyl<(1-10)> / CO2H / NH2 / NHOH
G5 = alkylene<EC (1-8) C, DC (0) M3>
G6 = alkyl<(6-20)> (SO (1-) G3) / alkenyl<(6-20)> / alkynyl<(6-20)> / cycloalkyl<(4-12)>
G7 = alkyl<(6-20)> (SO (1-) G3) / alkenyl<(6-20)> / alkynyl<(6-20)> / cycloalkyl<(4-12)> / aryl (SO (1-) G4) / (EX Ph / naphthyl / 165 / 173 / 181 / 195 / 207 / 215 / 223 / biphenylyl)















G8 = H / F / Cl / Br / I / alkyl<(1-3)> / CH=CH2 / SMe / SEt / OMe / OEt / CHO / CN
G9 = H / F / Cl / Br / I / Me
G10 = H / alkyl<(1-10)> (SO (1-) G3) / alkenyl<(2-10)> / alkynyl<(2-10)> / cycloalkyl<(3-8)> / aryl / aralkyl / alkoxy<(1-10)> (SO (1-) G3) / cycloalkyloxy<(4-8)> / OPh / F / Cl / Br / I / OH / CO2H / SH / CN / alkylthio<(1-10)> / arylthio / R<TX "thioacetal"> / alkoxycarbonyl<(1-10)> / NHNH2 / NH2 / NO2 / alkylamino<(1-10)> (SO OH) / dialkylamino<(1-10)> (SO OH) / Hy<EC (5-8) A (1-) Q (1-) N, AN (1-) N, RC (1), RS (1) M5 (1) X8> / 26 / 28 / 161



G11 = NH2 / alkylamino<(1-10)> (SO OH) / dialkylamino<(1-10)> (SO OH) / Hy<EC (5-8) A (1-) Q (1-) N, AN (1-) N, RC (1), RS (1) M5 (1) X8>
G12 = O / 31 / NH / S



G13 = alkyl<(1-10)>
G14 = alkylene (SO OH) / 33



G15 = Ak<BD (ALL) SE> (SO OH)
G16 = 35 / 38 / SO3H / 43 / 51 / 52 / 64 / 68 / 75 / 82 / 89 / 93







G17 = OH / alkoxy<(1-10)>
G18 = (1-8) CH2
G19 = NH2 / alkylamino<(1-10)> / dialkylamino<(1-10)> / 227



G20 = OH / alkoxy<(1-10)>
G21 = alkyl<(1-10)>
DER: and pharmaceutically acceptable salts
MPL: claim 1
NTE: additional ring formation possible

L10 ANSWER 74 OF 119 MARPAT COPYRIGHT 1998 ACS
(ALL HITs ARE ITERATION INCOMPLETES)

ACCESSION NUMBER:	124:117083 MARPAT	
TITLE:	Preparation of indole-3-glyoxylamides as sPLA2 inhibitors.	
INVENTOR(S):	Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth	
PATENT ASSIGNEE(S):	Lilly, Eli, and Co., USA	
SOURCE:	Eur. Pat. Appl., 78 pp. CODEN: EPXXDW	
	NUMBER	DATE
PATENT INFORMATION:	EP 675110 A1	951004
DESIGNATED STATES:	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE	
APPLICATION INFORMATION:	EP 95-302166	950331
PRIORITY APPLN. INFO.:	US 94-221916	940401
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	

MSTR 1 ITERATION INCOMPLETE



G1 = O / S
G2 = Ak<EC (7-20) C, BD (0-) D (0-) T> (SO) / Cb<(5-14)> (SO) / Hy<EC (5-14) A (1-3) Q (0-) N (0-) O (0-) S (0) OTHERQ> (SO) / 16 / 225 / (SC Ph (SO (1-2) Me) / naphthyl / 242 / 250 / 259 / 263 / 273 / 283 / 294 / 304 / 314 / 324 / 325 / 338 / 348 / 359 / 370 / 376 / 395 / 413)

G3—G4
16 17

G32—G31
225 226



242



250



259



263



273



283



294



304



314



324

G34—G35—Ph
325



338



348



359



370



376



395



413

G3 = R<TX "linking group"> / (SC alkylene<(1-2)> / G29 /
221-2 222-17)

G28—G29
221 222

G4 = Cb<(5-14)> (SO (1-) G16) /
Hy<EC (5-14) A (1-3) Q (0-) N (0-) O (0-) S (0) OTHERQ>
(SO) / (SC Ph (SO (1-) Me) / naphthyl / 28 / 36 / 45 / 49 /
59 / 69 / 80 / 90 / 100 / 110 / 111 / 124 / 134 / 145 / 156 /
418 / 437 / 455 / Ph (SR (1-) G16))



28



36



45



49



59











G13—G14—Ph
111















G5 = H / F / Cl / Br / I / alkyl<(1-3)> /
cycloalkyl<(3-4)> / cycloalkenyl<(3-4)> / alkoxy<(1-2)> /
alkylthio<(1-2)> / R / (SC cyclopropyl / Me / Et / Pr-n)
G6 = H / R / 20 / (SC 207 / 234)

G7—G8
20 21





G7 = R<TX "linking group"> / (SC 196-6 197-21 /
238-6 239-21)



G8 = R<TX "acidic group"> / (SC 163 / SO3H / 203 / 172 /
184 / 192 / 194 / 186)





o-C6H4CO2H
184



m-C6H4CO2H
192

p-C6H4CO2H
194



G9 = H / R / 23 / (SC 212 / 229)



G10 = R<TX "linking group"> / (SC 232-7 233-24 /
200-7 202-24)



G11 = CN / H
G12 = H / R / Cb<(5-14)> (SO) /
Hy<EC (5-14) A (1-3) Q (0-) N (0-) O (0-) S (0) OTHERQ>
(SO) / (SC alkyl<(1-6)> (SO aryl) / alkenyl<(2-6)> /
alkynyl<(2-6)> / aryl (SR alkyl) / cycloalkyl<(3-8)> /
cycloalkenyl<(3-8)> / Ph (SO (1-2) Me) / biphenylyl /
alkoxy<(1-6)> (SO (1-) G17) / alkenyloxy<(2-6)> /
alkynyloxy<(2-6)> / alkyl<(1-11)> (SR alkoxy<(1-11)>) /
alkoxy<(1-11)> (SR alkoxy<(1-11)>) / 460 /
alkylcarbonylamino<(1-11)> / alkoxyamino<(2-12)> /
alkoxyaminocarbonyl<(1-11)> / alkylamino<(2-12)> /
alkylthio<(1-6)> / alkylsulfinyl<(1-6)> /
alkylsulfonyl<(1-6)> (SO (1-) G17) /
alkyl<(2-6)> (SR (1-) G17) / alkyl<(1-6)> (SR OH) /
alkoxycarbonyl<(1-6)> / OCH2Ph / OPh / SPh / CHO / NH2 /
C(NH)NH2 / Br / CONH2 / CO2H / alkyl<EC (1-8) C, DC (0) M3>
(SR CO2H) / Cl / CN / 216 / F / NHNH2 / OH / NHOH / I / NO2 /
PO3H2 / SO3H)



G13 = phenylene
G14 = CH=CH / phenylene / G15
G15 = (0-8) CH2
G16 = R / (SC F / Cl / Br / I /
alkyl<(1-10)> (SO (1-) G17) / alkoxy<(1-10)> /
alkylthio<(1-10)>)
G17 = F / Cl / Br / I
G18 = 173 / alkoxy<(1-10)> / OH / 175



G19 = (1-8) CH2
G20 = 178 / 180



G21 = NH2 / alkylamino<(1-10)> / dialkylamino<(1-10)>
G22 = alkyl<(1-10)>
G23 = H / R
G24 = CH2 / O / NH / S
G25 = (1-7) CH2 (SO)
G26 = phenylene
G27 = phenylene
G28 = CH2 / O / 223 / S



G29 = (1-5) CH2 (SO)
G30 = H / alkyl<(1-10)>
G31 = Ak<EC (7-20) C, BD (0-) D (0-) T> (SO)
G32 = R<TX "linking group"> / (SC alkylene<(1-2)> / G29 / 227-2 228-226)



G33 = Me / CH2CH2Ph
G34 = phenylene
G35 = CH=CH / phenylene / G15
G36 = alkyl<(1-11)>
DER: or pharmaceutically acceptable salts, solvates or prodrug derivatives
MPL: claim 1
NTE: substitution is restricted

L10 ANSWER 54 OF 119 MARPAT COPYRIGHT 1998 ACS
(ALL HITs ARE ITERATION INCOMPLETES)

ACCESSION NUMBER:	124:260835 MARPAT	
TITLE:	Indole-2-carboxylic acids as nonpeptide endothelin antagonists	
INVENTOR(S):	Berryman, Kent A.; Bunker, Amy M.; Doherty, Annette M.; Edmunds, Jeremy J.	
PATENT ASSIGNEE(S):	Warner-Lambert Co., USA	
SOURCE:	U.S., 12 pp. CODEN: USXXAM	
	NUMBER	DATE
PATENT INFORMATION:	US 5482960 A	960109
APPLICATION INFORMATION:	US 94-339381	941114
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	

MSTR 1A ITERATION INCOMPLETE



G1 = H
G2 = H
G3 = (0-4) CH2
G4 = 41 / 50 / (EX H / cycloalkyl<(3-12)>)





G5 = H / F / Cl / Br / I / alkyl<(1-6)> / OH / 14 / NH2 / SH / NO2 / N3 / CHO / 18 / CO2H / 20 / CONH2 / 25 / 32 / 35 / CN / CF3 / 63 / OCOMe / 66 / Ph / 68





G6 = alkyl<(1-4)> / Ph / CH2Ph
G7 = O / NH / 16 / S



G8 = O / NH / 23



G9 = NH2 / 27 / 29



G10 = NH / S / O
G11 = (1-3) CH2
G12 = C(O) / NULL
G13 = H / alkyl<(1-4)> / Ph / CH2Ph
G14 = H / alkyl<(1-7)> / alkenyl<(2-7)> / alkynyl<(2-7)> / cycloalkyl<(3-12)> / Ph (SO) / COPh / 77 / OH / 80 / NO2 / N3 / CHO / 82 / CO2H / CONH2 / 84 / 87 / 90 / CN / CF3 / 92 / OCOMe / 95 / 97





G15 = O / NH / S / S(O) / SO2
G16 = (0-4) CH2
G17 = Ph / naphthyl
G18 = H / CO2H / 103 / 109 / 121 / SO3H / 122 / PO3H2 / 126 / 128 / 135 / 140





G19 = alkyl<(1-6)> / CF3 / 106 / Ph (SO) / CH2Ph (SO)



G20 = C(O) / SO2
G21 = NH / 131



G22 = H / alkyl<(1-6)> / CF3 / 133 / Ph (SO) / CH2Ph (SO)



G23 = S / S(O) / SO2
G24 = Ph (SO (1-) G25) / 172 / 181



G25 = F / Cl / Br / I / OH / SH / NH2 / 146 / NO2 / N3 / CHO / 148 / 150 / CONH2 / 153 / 156 / CN / CF3 / 158 / OCOMe / 161 / Ph / 163 / (EX OMe / OPr-n / OCH2Ph)





G26 = H / F / Cl / Br / I / OH / SH / NH2 / 194 / NO2 / N3 / CHO / 196 / 198 / CONH2 / 201 / 204 / CN / CF3 / 206 / OCOMe / 209 / Ph / 211 / (EX OMe / OPr-n / OCH2Ph)





G27 = H / alkyl<(1-7)> / alkenyl<(2-7)> / alkynyl<(2-7)> / cycloalkyl<(3-12)> / Ph (SO) / COPh / 216 / OH / 219 / NO2 / N3 / CHO / 221 / CO2H / CONH2 / 223 / 226 / 229 / CN / CF3 / 231 / OCOMe / 234 / 236





G28 = H / alkyl<(1-7)> / alkenyl<(2-7)> / alkynyl<(2-7)> / cycloalkyl<(3-12)> / Ph (SO) / COPh / 241 / OH / 244 / NO2 / N3 / CHO / 246 / CO2H / CONH2 / 248 / 251 / 254 / CN / CF3 / 256 / OCOMe / 259 / 261





G29 = H / alkyl<(1-7)> / alkenyl<(2-7)> / alkynyl<(2-7)> / cycloalkyl<(3-12)> / Ph (SO) / COPh / 266 / OH / 269 / NO2 / N3 / CHO / 271 / CO2H / CONH2 / 273 / 276 / 279 / CN / CF3 / 281 / OCOMe / 284 / 286





G1 +G2 = NULL
G14+G27= OCH2O
G27+G28= OCH2O
G28+G29= OCH2O
DER: or pharmaceutically acceptable acid addition or base salts
MPL: claim 1
NTE: also incorporates broader disclosure

CCESSION NUMBER:	125:275644 MARPAT
TITLE:	Preparation of aryl/heteroaryl-substituted acylaminoalkanecarboxamides and acylaminoalkenecarboxamides as neurokinin 1 antagonists
INVENTOR(S):	Gerspacher, Marc; Von Sprecher, Andreas; Roggo, Silvio; Mah, Robert; Ofner, Silvio; Veenstra, Siem Jacob; Betschart, Claudia; Auberson, Yves; Schilling, Walter
PATENT ASSIGNEE(S):	Switz.
SOURCE:	PCT Int. Appl., 143 pp. CODEN: PIXXD2

	NUMBER	DATE
PATENT INFORMATION:	WO 9626183 A1	960829
DESIGNATED STATES:	W: AL, AM, AU, BB, BG, BR, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KP, KR, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AZ, BY, KG, KZ, RU, TJ, TM RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG	
APPLICATION INFORMATION:	WO 96-EP555	960209
PRIORITY APPLN. INFO.:	EP 95-810117	950222
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	

MSTR 1 ITERATION INCOMPLETE



G1 = aryl (SO) / heteroaryl (SO) /
(SC Ph (SO (1-2) G11) / pyridyl (SO (1-2) G11))
G2 = NH / 6



G3 = alkyl<(1-7)> (SO G12) / (SC Me / 18 / CHPh2)



G4 = aryl (SO) / heteroaryl (SO) /
(SC Ph (SO (1-2) G13) / naphthyl (SO (1-2) G13) /
indolyl (SO (1-2) G13) / 59)



G5 = alkylene<(1-7)> / alkenylene<EC (2-7) C, BD (1-2) D>
/ (SC CH2CH2 / CH=CH / CH2 / 75-1 76-11)



G6 = 13 / Hy<EC (1-) N, AN (1-) N> (SO) /
(SC piperidino (SO (1-2) G28) / aziridino (SO alkyl<(1-7)>) /
136 / piperazino (SO G29) / morpholino / 79 / 94 / 109 /
117 / 121)





G7 = H / alkyl<(1-7)> / aryl (SO) / heteroaryl (SO) /
(SC Ph (SO (1-2) G13) / naphthyl (SO (1-2) G13) /
indolyl (SO (1-2) G13))

G8 = H / R / (SC alkyl<(1-7)> (SO G17) /
alkenyl<(2-7)> (SO) / alkynyl<(2-7)> (SO) /
cycloalkyl (SO G20) / Hy<EC (0-) N (0-) O (0-) S (0) OTHERQ,
AR (0), BD (ALL) SE> (SO) / aryl (SO (1-) G24) /
heteroaryl (SO (1-) G26) / Hy<AR (0), BD (1-2) D, RC (1),
RS (1) E6> (SO) / Hy<AR (0), BD (1) D, RC (1), RS (1) E5>
(SO) / 16 / 32 / 36 / cyclohexyl / 44 / 55 / 70 / Ph /
naphthyl / pyridyl / quinolinyl / pyrimidinyl / thiazolyl /
thiadiazolyl / isothiazolyl / indolyl)







G9 = alkyl<(1-7)> (SO) / alkenyl<(2-7)> (SO) / aryl (SO) / heteroaryl (SO) / Ph (SO alkyl<(1-7)>)
G10 = H / R / (SC alkyl<(1-7)> (SO G19) / alkenyl<(2-7)> (SO) / alkynyl<(2-7)> (SO) / aryl (SO) / heteroaryl (SO) / acyl / Pr-i)
G11 = alkyl<(1-7)> / CF3 / F / Cl / Br / I / OH / alkoxy<(1-7)> / NO2
G12 = aryl (SO) / (SC Ph (SO (1-2) G13))
G13 = alkyl<(1-7)> / CF3 / F / Cl / Br / I / OH / alkoxy<(1-7)>
G14 = H / Cl
G15 = 20 / 2-naphthyl / 25



G16 = H / Me
G17 = R / aryl (SO G25) / heteroaryl (SO) / Ph / naphthyl / indolyl / pyridyl / quinolinyl / pyrimidinyl / thiazolyl / thiadiazolyl / isothiazolyl / alkoxycarbonyl<(1-7)> / CONH2 / CN / dialkylamino<(1-7)> / piperidino / morpholino / OH / COPh / cycloalkyl (SO alkoxycarbonyl<(1-7)>)
G18 = Hy<EC (0-) N (0-) O (0-) S (0) OTHERQ> (SO)
G19 = R / OH / CN
G20 = R / OH
G21 = H / alkyl<(1-7)> / CHO / alkylcarbonyl<(1-6)> / alkyl<(1-7)> (SR dialkylamino<(1-7)>) / alkoxy<(1-7)> (SR Ph)
G22 = H / alkylthio<(1-7)> / alkyl<(1-7)> (SR CN)
G23 = H / alkyl<(1-7)>
G24 = R / alkyl<(1-7)> / F / Cl / Br / I / OH / alkoxy<(1-7)> / dialkylamino<(1-7)> / morpholino / NO2 / alkoxycarbonyl<(1-7)>
G25 = OH / alkoxy<(1-7)> / F / Cl / Br / I
G26 = R / alkyl<(1-7)> / F / Cl / Br / I / alkylcarbonyl<(1-6)> (SR (1-) G27)
G27 = F / Cl / Br / I
G28 = NHCHO / alkylcarbonylamino<(1-6)> / Ph / alkyl<(1-7)> (SO OH) / dialkylamino<(1-7)> / OH
G29 = Ph (SO alkoxy<(1-7)>) / alkyl<(1-7)> (SR G30) / alkyl<(1-7)> (SR 137)



G30 = Ph (SR (1-) G27)
G31 = Hy<EC (1) Q (1) N, AN (1) N, AR (0), BD (ALL) SE>

DER: or salts

US PAT NO: 4,582,848 [IMAGE AVAILABLE] L1: 1 of 2
TITLE: 2-substituted-3-indolamines and use thereof as anti-diabetics
INVENTOR: Jeffrey Nadelson, Denville, NJ
DATE ISSUED: Apr. 15, 1986

ABSTRACT:
This disclosure relates to substituted indolamines, which exhibit anti-diabetic activity, having the formula: ##STR1## where m is an integer from 1 to 4,
x represents hydrogen or --OH
R represents Ar or ##STR2## and Ar represents ##STR3## R.sub.1 represents hydrogen, fluoro, chloro, lower alkyl or lower alkoxy, R.sub.2 and R.sub.3 each, independently, represent lower alkyl, or R.sub.2 and R.sub.3 together with N represent ##STR4## wherein n is 1, 2 or 3,
R.sub.4 represents hydrogen or lower alkyl, and
R.sub.5 represents hydrogen or lower alkyl, unsubstituted phenyl or phenyl substituted with fluoro, chloro, lower alkyl or lower alkoxy, or
or pharmaceutically acceptable acid addition salts thereof.
US-CL-CURRENT: 514/419; 548/507

US PAT NO: 3,691,194 [IMAGE AVAILABLE] L1: 2 of 2
TITLE: 3-**INDOLE-GLYOXAMIDES**
INVENTOR: Zinin B. Papanastassiou, Lexington, MA
John L. Neumeyer, Wayland, MA
DATE ISSUED: Sep. 12, 1972

ABSTRACT:
New 3-**indole-glyoxamides** and (3-indole)-lower-alkylamines having useful C.N.S. depressant activity and prepared, respectively, by reaction of a 3-indoleglyoxalyl halide or a (3-indole)-lower-alkyl halide with an appropriate amino.
US-CL-CURRENT: 548/468, 507